{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:54Z","timestamp":1787013594092,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The helicase\u2013primase inhibitor amenamevir (AMNV) was approved for herpes zoster in Japan in 2017. The authors conducted a 1\u2010month postmarketing observational study to evaluate the real\u2010world safety and efficacy (cutaneous improvement and pain resolution) of AMNV in patients with herpes zoster. Of the 3453 patients registered between March 2018 and December 2020, 3110 were included in the safety analyses. The mean age (\u00b1standard deviation) was 63.7\u2009\u00b1\u200917.5\u2009years, with 57.9% of patients aged \u226565\u2009years. Most patients had mild (53.3%) or moderate (41.0%) cutaneous lesions. Regarding pain, 43.9%, 25.6%, and 12.5% of patients had pain at the levels of 1\u20133, 4\u20136, and 7\u201310 on the numerical rating scale. In total, 30.0%, 27.2%, and 16.1% of patients were concomitantly treated with analgesics: acetaminophen, nonsteroidal anti\u2010inflammatory drugs, and Ca\n                    <jats:sup>2+<\/jats:sup>\n                    channel \u03b1 2\u03b4 ligands, respectively, and 10.6% were treated with topical antiherpetic drugs. Adverse drug reactions occurred in 0.77% of patients, including four serious adverse drug reactions in four patients (hyponatremia, thrombocytopenia, rash, and rhabdomyolysis). Regarding important potential risks, renal disorder, cardiovascular events, and decreased platelets were observed in one, one, and two patients, respectively. Concerning efficacy, the cutaneous improvement rate (significantly improved or improved) was 95.5%, with significantly higher improvement rates in patients treated with AMNV for 7\u2009days and in patients with less severe cutaneous lesions or less pain. Factors affecting the time to pain resolution were the severity of cutaneous lesions and pain at the start of AMNV treatment and older age. This study demonstrated that the AMNV is safe and effective in patients with herpes zoster in a real\u2010world clinical setting.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.16876","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T01:27:59Z","timestamp":1688434079000},"page":"1287-1300","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world safety and efficacy of amenamevir in patients with herpes zoster in Japan: A postmarketing observational study (\n                    <scp>REWARD<\/scp>\n                    )"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinich","family":"Imafuku","sequence":"first","affiliation":[{"name":"Department of Dermatology Fukuoka University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0869-6504","authenticated-orcid":false,"given":"Kenta","family":"Korematsu","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; PMS Department Maruho Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Mori","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; PMS Department Maruho Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kani","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; PMS Department Maruho Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Matsui","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; PMS Department Maruho Co., Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26041132"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.006"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq198"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13948"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0481-y"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.630"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0642-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13081547"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3812\/jocd.37.641"},{"key":"e_1_2_7_11_1","unstructured":"Maruho Co. Ltd.Amenalief 200 mg tablet (in Japanese) [Internet].Osaka (Japan):Maruho Co. Ltd;2020[updated 2020 Dec; cited 2021 Nov 6].https:\/\/www.info.pmda.go.jp\/go\/pack\/6250046F1028_1_05\/?view=frame&style=XML&lang=ja"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12379"},{"key":"e_1_2_7_13_1","first-page":"799","article-title":"Large\u2010scale herpes zoster epidemiological survey (Miyazaki study) in the local dermatologist community: 75789 cases (1997\u20132011)","volume":"29","author":"Toyama N","year":"2012","journal-title":"J Jpn Organ Clin Dermatol"},{"key":"e_1_2_7_14_1","unstructured":"Elderly population in Japan.Statistics topics No.129 Statistics of Japan. Ministry of Internal affairs and Communications (in Japanese). [published 2021 Sep 19 cited 2023 Feb 21].https:\/\/www.stat.go.jp\/data\/topics\/topi1291.html"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104829"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01375-1"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02770836"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/421942"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-37"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-402"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02376.x"},{"key":"e_1_2_7_22_1","article-title":"Managing chronic pain in the elderly: an overview of the recent therapeutic advancements","volume":"10","author":"Ali A","year":"2018","journal-title":"Cureus"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3626"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00874"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-018-2501-0"},{"key":"e_1_2_7_26_1","volume-title":"Executive summary of the clinical guidelines of pharmacotherapy for neuropathic pain: second edition (in Japanese) [Internet]","author":"Japanese Society of Pain Clinicians","year":"2022"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000140708.62856.72"},{"key":"e_1_2_7_28_1","first-page":"9","article-title":"Pharmacological management of the neuropathic pain","volume":"18","author":"IASP","year":"2010","journal-title":"Pain Clin Update"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2786151"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/510206"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T05:20:12Z","timestamp":1696396812000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/1346-8138.16876"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16876","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"2023-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}